The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Open accessAbstract
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [81]
In the citing paper
“Because cardiovascular event rates are increased in people with diabetes and established ASCVD, intensive therapy is indicated and has been shown to be of bene fi t in multiple large meta-analyses and randomized cardiovascular outcomes trials (91,99,105,107,108).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“In the PACIFIC study740), which was a multicenter observational registry study on ACS, the incidence rate of fatal and nonfatal myocardial infarction was high, at 35/1,000 person-years, despite approximatively 80% subjects being administered statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“The results of these studies have found that, compared to patients with normal renal function, the risk for cardiovascular events, including cerebrovascular disease, cardiac death, and total mortality increases by 2–3-fold in those with CKD even when the CKD is mild.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events (200–202), have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL cholesterol of <70 mg/dl led to a significant reduction in further events.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D. J., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,475
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 401–500 of 1,027
2017 Taiwan lipid guidelines for high risk patients
Li, Y., Ueng, K., Jeng, J., Charng, M., Lin, T., Chien, K., Wang, C., Chao, T., Liu, P., Su, C., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 166
Oxidized phospholipids in cardiovascular disease
Tsimikas, S., & Witztum, J. L. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00937-4 · Cited by 166
The Safety of Rosuvastatin as Used in Common Clinical Practice
Alsheikh-Ali, A. A. A., Ambrose, M. S., Kuvin, J. T., & Karas, R. H. (2005) · Circulation · doi:10.1161/circulationaha.105.555482 · Cited by 166
Dyslipidemia and cardiovascular risk: the importance of early prevention
Miller, M. J. (2009) · QJM · doi:10.1093/qjmed/hcp065 · Cited by 165
From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells
Leone, A. M., Valgimigli, M., Giannico, M. B., Zaccone, V., Perfetti, M., D’Amario, D., Rebuzzi, A. G., & Crea, F. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp078 · Cited by 164
Ng, C. J., Bourquard, N., Grijalva, V. R., Hama, S. Y., Shih, D. M., Navab, M., Fogelman, A. M., Lusis, A. J., Young, S. G., & Reddy, S. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605379200 · Cited by 164
Carbamylated low-density lipoprotein induces endothelial dysfunction
Speer, T., Owala, F. O., Holy, E. W., Zewinger, S., Frenzel, F., Stähli, B. E., Razavi, M., Triem, S., Cvija, H., Rohrer, L., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu111 · Cited by 164
Rodríguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4052 · Cited by 163
Hayward, R. A., Hofer, T. P., & Vijan, S. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-7-200610030-00010 · Cited by 163
Framingham risk score and prediction of coronary heart disease death in young men
Berry, J. D., Lloyd‐Jones, D. M., Garside, D. B., & Greenland, P. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.03.042 · Cited by 162
Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00040-8 · Cited by 161
Self-citationTardif, J., L’Allier, P. L., Ibrahim, R., Grégoire, J. C., Nozza, A., Cossette, M., Kouz, S., Lavoie, M.-A., Paquin, J., Brotz, T. M., et al. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.937169 · Cited by 161
Newman, C. B., Tsai, J., Szarek, M. J., Luo, D., & Gibson, E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.108 · Cited by 161
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv072 · Cited by 160
C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield, M. B. (2005) · PubMed · Cited by 160
Jafri, H., Alsheikh-Ali, A. A. A., & Karas, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.069 · Cited by 160
Understanding the molecular mechanisms of statin pleiotropic effects
German, C. A., & Liao, J. K. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03492-6 · Cited by 160
Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met
Yan, A. T.-K., Yan, R. T., Tan, M., Hackam, D. G., Leblanc, K., Kertland, H. R., Tsang, J. L. Y., Jaffer, S., Kates, M. L., Leiter, L. A., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.015 · Cited by 159
Vascular Biomarkers and Surrogates in Cardiovascular Disease
Tardif, J., Heinonen, T. M., Orloff, D. G., & Libby, P. (2006) · Circulation · doi:10.1161/circulationaha.105.598987 · Cited by 159
Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease
Rosenson, R. S., Kent, S. T., Brown, T. M., Farkouh, M. E., Levitan, E. B., Yun, H., Sharma, P., Safford, M. M., Kilgore, M. L., Muntner, P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.088 · Cited by 158
Catapano, A. L., & Papadopoulos, N. J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.044 · Cited by 158
Mukhtar, R., Reid, J., & Reckless, J. P. D. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2005.00461.x · Cited by 158
Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.009 · Cited by 157
Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M., & Braunwald, E. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181735 · Cited by 157
Self-citationHigh-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.
Nelson, A. J., Haynes, K., Shambhu, S., Eapen, Z. J., Cziraky, M. J., Nanna, M. G., Calvert, S. B., Gallagher, K., Pagidipati, N. J., & Granger, C. B. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.048 · Cited by 157
Nicholls, S. J., Cutri, B., Worthley, S. G., Kee, P. H., Rye, K.-A., Bao, S., & Barter, P. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000184760.95957.d6 · Cited by 156
Assessing and Reducing the Cardiac Risk of Noncardiac Surgery
Auerbach, A. D., & Goldman, L. (2006) · Circulation · doi:10.1161/circulationaha.105.573113 · Cited by 155
Vavvas, D. G., Daniels, A. B., Kapsala, Z., Goldfarb, J. W., Ganotakis, E. S., Loewenstein, J. I., YOUNG, L. H. Y., Gragoudas, E. S., Eliott, D., Kim, I. K., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.01.033 · Cited by 155
RhoA/Rho-kinase and vascular diseases: what is the link?
Nunes, K. P., Rigsby, C. S., & Webb, R. C. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0460-1 · Cited by 155
Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy
Schoenhagen, P., Tuzcu, E. M., Apperson-Hansen, C., Wang, C., Wolski, K., Lin, S., Sipahi, İ., Nicholls, S. J., Magyar, W. A., Loyd, A., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.585703 · Cited by 154
Yonemura, A., Momiyama, Y., Fayad, Z. A., Ayaori, M., Ohmori, R., Higashi, K., Kihara, T., Sawada, S., Iwamoto, N., Ogura, M., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.039 · Cited by 154
Bonaca, M. P., Gutierrez, J. A., Cannon, C., Giugliano, R., Blazing, M., Park, J.-G., White, J., Tershakovec, A., & Braunwald, E. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30290-0 · Cited by 153
Self-citationLDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
Ravnskov, U., de Lorgeril, M., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M. E., Langsjoen, P. H., Mascitelli, L., et al. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1519391 · Cited by 153
Nrf2 for cardiac protection: pharmacological options against oxidative stress
Chen, Q. M. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.06.005 · Cited by 151
Coronary Heart Disease in Patients With Diabetes
Berry, C., Tardif, J., & Bourassa, M. G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.045 · Cited by 151
Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes
Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.017 · Cited by 150
Self-citationStatin‐associated autoimmune myopathy and anti‐HMGCR autoantibodies
Mohassel, P., & Mammen, A. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23854 · Cited by 150
Statins in Acute Ischemic Stroke: A Systematic Review
Hong, K., & Lee, J. S. (2015) · Journal of Stroke · doi:10.5853/jos.2015.17.3.282 · Cited by 150
Stabilisation of atherosclerotic plaques
Bentzon, J. F., Daemen, M. J. A. P., Falk, E., Garcia-Garcia, H., Herrmann, J., Hoefer, I. E., Jukema, J. W., Krams, R., Kwak, B. R., Marx, N., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-12-0784 · Cited by 150
Nherera, L. M., Marks, D., Minhas, R., Thorogood, M., & Humphries, S. E. (2011) · Heart · doi:10.1136/hrt.2010.213975 · Cited by 149
Brunham, L. R., Singaraja, R. R., & Hayden, M. R. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111214 · Cited by 148
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23390 · Cited by 148
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials
Gould, A. L., Davies, G., Alemao, E., Yin, D., & Cook, J. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.05.012 · Cited by 147
Pedersen, T. R., & Tobert, J. A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.12.2583 · Cited by 147
Makki, N. M., Brennan, T. M. H., & Girotra, S. R. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613503294 · Cited by 147
LaRosa, J. C., Grundy, S. M., Kastelein, J. J. P., Kostis, J. B., & Greten, H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.102 · Cited by 147
Mills, E. J., O’Regan, C., Eyawo, O., Wu, P., Mills, F. P., Berwanger, O. B., & Briel, M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr035 · Cited by 147
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 147
Marshall, J. C., Vincent, J., Guyatt, G. H., Angus, D. C., Abraham, E. H., Bernard, G. R., Bombardier, C., Calandra, T., Jørgensen, H. S., Sylvester, R. J., et al. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000174478.70338.03 · Cited by 146
März, W., Genser, B., Drechsler, C., Krane, V., Grammer, T. B., Ritz, E., Stojaković, T., Scharnagl, H., Winkler, K., Holme, I., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09121010 · Cited by 146
Beest, F. J. A. P., Termorshuizen, F., Goettsch, W., Klungel, O. H., Kastelein, J. J. P., & Herings, R. M. C. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl391 · Cited by 145
Preoperative statin therapy for patients undergoing cardiac surgery
Liakopoulos, O. J., Kuhn, E. W., Slottosch, I., Wassmer, G., & Wahlers, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008493.pub2 · Cited by 145
RetractedMcKenney, J. M., Davidson, M. H., Shear, C. L., & Revkin, J. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.066 · Cited by 144
Clinical efficacy and safety of statins in managing cardiovascular risk
Kapur, N. K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1653 · Cited by 143
Statins inhibit Rho kinase activity in patients with atherosclerosis
Nohria, A., Pršić, A., Liu, P., Okamoto, R., Creager, M. A., Selwyn, A. P., Liao, J. K., & Ganz, P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.023 · Cited by 143
Afilalo, J., Majdan, A. A., & Eisenberg, M. J. (2007) · Heart · doi:10.1136/hrt.2006.112508 · Cited by 143
Hippisley‐Cox, J., & Coupland, C. A. C. (2005) · BMJ · doi:10.1136/bmj.330.7499.1059 · Cited by 142
Mahmarian, J. J., Dakik, H. A., Filipchuk, N. G., Shaw, L. J., Iskander, S., Ruddy, T. D., Keng, F. Y. J., Henzlova, M. J., Allam, A. H., Moyé, L. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.068 · Cited by 140
Mhaimeed, O., Burney, Z. A., Schott, S. L., Kohli, P., Marvel, F. A., & Martin, S. S. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100649 · Cited by 140
Fichtlscherer, S., Schmidt‐Lucke, C., Bojunga, S., Rössig, L., Heeschen, C., Dimmeler, S., & Zeiher, A. M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi881 · Cited by 140
Wenger, N. K., Lewis, S. J., Herrington, D. M., Bittner, V., Welty, F. K., & for the Treating to New Targets Study Steering Committee and Investigators (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-1-200707030-00002 · Cited by 139
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Exposure to statins and risk of common cancers: a series of nested case-control studies
Vinogradova, Y., Coupland, C. A. C., & Hippisley‐Cox, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-409 · Cited by 139
Ye, X., Kong, W., Zafar, M. I., & Chen, L.-L. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0851-z · Cited by 138
Farmakis, D. T., Mueller, C. E., & Apple, F. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa083 · Cited by 138
Collard, C. D., Body, S. C., Shernan, S. K., Wang, S. V., & Mangano, D. T. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.04.009 · Cited by 138
Averitt, A. J., Weng, C., Ryan, P., & Perotte, A. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0277-8 · Cited by 137
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 139
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Circulation · doi:10.1161/cir.0000000000000626 · Cited by 137
Non-adherence to statin therapy: a major challenge for preventive cardiology
Bates, T., Connaughton, V., & Watts, G. F. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903376186 · Cited by 137
Hagiwara, N., Kawada-Watanabe, E., Koyanagi, R., Arashi, H., Yamaguchi, J., Nakao, K., Tobaru, T., Tanaka, H., Oka, T., Endoh, Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx162 · Cited by 136
Beyond Low-Density Lipoprotein Cholesterol
Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.045 · Cited by 136
Long-Term Prognostic Value of Neopterin
Ray, K. K., Morrow, D. A., Sabatine, M. S., Shui, A. M., Rifai, N., Cannon, C. P., & Braunwald, E. (2007) · Circulation · doi:10.1161/circulationaha.106.666511 · Cited by 136
Self-citationLeft Ventricular Post-Infarct Remodeling
van der Bijl, P., Abou, R., Goedemans, L., Gersh, B. J., Holmes, D. R., Marsan, N. A., Delgado, V., & Bax, J. J. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.08.014 · Cited by 135
Loss of Imprinting ofIGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk
Kaneda, A., & Feinberg, A. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2959 · Cited by 135
Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134
Reddy, V. S., Bui, Q. T., Jacobs, J. R., Begelman, S. M., Miller, D. P., & French, W. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.12.006 · Cited by 134
Schiele, F., Gale, C. P., Bonnefoy‐Cudraz, E., Capuano, F., Claeys, M. J., Danchin, N., Fox, K. A. A., Huber, K., Iakobishvili, Z., Lettino, M., et al. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616643053 · Cited by 134
Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting
Cziraky, M. J., Watson, K. E., & Talbert, R. L. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s8-a.1 · Cited by 134
Nishio, R., Shinke, T., Otake, H., Nakagawa, M., Nagoshi, R., Inoue, T., Kozuki, A., Hariki, H., Osue, T., Taniguchi, Y., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.025 · Cited by 133
Wilke, R. A., Moore, J. H., & Burmester, J. K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200506000-00007 · Cited by 133
Lewis, E. F., Velazquez, E. J., Solomon, S. D., Hellkamp, A. S., McMurray, J. J. V., Mathias, J., Rouleau, J. L., Maggioni, A. P., Swedberg, K. B., Køber, L., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn062 · Cited by 133
Self-citationNakano, S., Kohsaka, S., Chikamori, T., Fukushima, K., Kobayashi, Y., Kozuma, K., Manabe, S., Matsuo, H., Nakamura, M., Ohno, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-1041 · Cited by 132
Ii, M., & Losordo, D. W. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.06.012 · Cited by 132
Gibson, C. M., Pride, Y. B., Hochberg, C. P., Sloan, S., Sabatine, M. S., & Cannon, C. P. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.010 · Cited by 132
Self-citationGrandin, E. W., Jarolı́m, P., Murphy, S. A., Ritterova, L., Cannon, C. P., Braunwald, E., & Morrow, D. A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.174359 · Cited by 131
Self-citationAntiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond
Aday, A. W., & Ridker, P. M. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00062 · Cited by 131
Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans
Choi, J., Lee, M., Cho, J.-Y., Lee, J.-E., Kim, K. H., & Park, K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100267 · Cited by 131
Navarese, E. P., Kowalewski, M., Andreotti, F., van Wely, M., Camaro, C., Kolodziejczak, M., Gorny, B., Wirianta, J., Kubica, J., Kelm, M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.02.034 · Cited by 130
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655761 · Cited by 130
Pletcher, M. J., Bibbins-Domingo, K., Liu, K., Sidney, S., Lin, F., Vittinghoff, E., & Hulley, S. B. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00004 · Cited by 129
Hirsh, B. J., Smilowitz, N. R., Rosenson, R. S., Fuster, V., & Sperling, L. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.030 · Cited by 129
Sever, P., Chang, C. L., Gupta, A. K., Whitehouse, A., & Poulter, N. R. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr333 · Cited by 129
Davidson, M. H., McKenney, J. M., Shear, C. L., & Revkin, J. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.067 · Cited by 129
National lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128
High-Dose Atorvastatin Reduces Periodontal Inflammation
Subramanian, S. S., Emami, H., Vucic, E., Singh, P., Vijayakumar, J., Fifer, K. M., Alon, A., Shankar, S. S., Farkouh, M. E., Rudd, J. H. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.1627 · Cited by 128
Mani, P., Puri, R., Schwartz, G. G., Nissen, S. E., Shao, M., Kastelein, J. J. P., Menon, V., Lincoff, A. M., & Nicholls, S. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0179 · Cited by 128
Moreno, P., & Fuster, V. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.077 · Cited by 128
Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation · doi:10.1161/circulationaha.116.024604 · Cited by 127
Self-citation
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-08
- Volume
- 350
- Issue
- 15
- Pages
- 1495-1504
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159449551
- Cited by
- 4,938
- References
- 32
- Citations by year
- 2026: 87 · 2025: 84 · 2024: 121 · 2023: 117 · 2022: 120 · 2021: 129 · 2020: 147 · 2019: 163 · 2018: 155 · 2017: 215 · 2016: 178 · 2015: 216 · 2014: 213 · 2013: 215 · 2012: 229
- FWCI
- 442.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, statins, intensive lipid-lowering therapy, LDL cholesterol, pravastatin, atorvastatin, non-inferiority, major adverse cardiovascular events, revascularization, myocardial infarction, stroke, unstable angina
- MeSH terms
- Atorvastatin, Angina, Unstable, Anticholesteremic Agents, Cardiovascular Diseases, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
